Mesoblast publishes Phase 2 trial results of cell therapy for kidney disease
Mesoblast announced results from the randomized, placebo-controlled Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cell product candidate, MPC-300-IV, in patients with diabetic kidney disease, published in the current issue of the peer-reviewed journal EBioMedicine. The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in a Phase 2 trial in adult patients with type 2 diabetic nephropathy. The Phase 2, double-blind, randomized, placebo-controlled, dose-escalating trial evaluated MPC-300-IV in patients with type 2 diabetes and moderate to severe renal impairment, stage 3b-4 chronic kidney disease, who were already on a stable regimen of the standard of care therapy for diabetic nephropathy. Safety profile for MPC-300-IV treatment was similar to placebo, with no treatment-related adverse events. Efficacy testing showed that patients receiving a single MPC infusion at either dose had improved renal function relative to placebo.